Furthermore, we show, in agreement with Morais-Santos et al. that CHC, an MCT1 inhibitor, at concentrations up to 5 mM, is not toxic to MCT1-positive breast cancer cells, such as BT20. Here, SLC16A1 is linked to breast carcinoma.